51766 | Huvepharma NV. | Salinomycin sodium 120 g/kg(Sacox 120 microGranulate)Salinomycin sodium 200 g/kg(Sacox 200 microGranulate) | Additive composition(Sacox120 microGranulate):- Salinomycin sodium: 114-132 g/kg
- Silicon dioxide: 10-100 g/kg
- Calcium carbonate: 500-700 g/kg
Solid form(Sacox 200 microGranulate):- Salinomycin sodium: 190-220 g/kg
- Silicon dioxide: 50-150 g/kg
- Calcium carbonate: 50-150 g/kg
Solid formCharacterisation of the active substanceSalinomycin sodium,C42H69Na O11,CAS number: 55721-31-8,sodium salt of a polyether monocarboxylic acid produced by fermentation of Streptomyces azureus (DSM 32267)Related impurities:- ≤ 10 mg elaiophylin/kg salinomycin sodium.
- ≤ 2 g 17-epi-20-desoxy-salinomycin/kg salinomycin sodium.
- ≤ 10 g 20-desoxysalinomycin/kg salinomycin sodium.
- ≤ 10 g 18,19-dihydrosalinomycin/kg salinomycin sodium.
- ≤ 10 g methylated salinomycin/kg salinomycin sodium.
Analytical methodFor the quantification of salinomycin in the feed additive:High Performance Liquid Chromatography using post-column derivatisation coupled to spectrophotometric detection (HPLC-PCD-UV-Vis).For the quantification of salinomycin in premixtures and feedingstuffs:High Performance Liquid Chromatography using post-column derivatisation coupled to spectrophotometric detection (HPLC-PCD-UV-Vis) — EN ISO 14183. | Chickens for fattening | — | 50 | 70 | 1.The additives shall be incorporated in compound feed in the form of a premixture.2.The following shall be indicated in the instructions for use:"Dangerous for equines and turkeys.This feedingstuff contains an ionophore:simultaneous use with certain medicinal substances (e.g. tiamulin) can be contra-indicated".3.Salinomycin sodium shall not be mixed with other coccidiostats.4.A post-market monitoring program on the resistance to bacteria and Eimeria spp. shall be planned and executed by the holder of authorisation.5.Zero days of withdrawal time.6.For users of the additive and premixtures, feed business operators shall establish operational procedures and organisational measures to address potential risks resulting from its use. Where those risks cannot be eliminated or reduced to a minimum by such procedures and measures, the additive and premixtures shall be used with personal protective equipment, including breathing, eyes and skin protections. | 9 November 2027 | 150 μg salinomycin sodium/kg of liver;40 μg salinomycin sodium/kg of kidney;15 μg salinomycin sodium/kg of muscle, and 150 μg salinomycin sodium/kg. skin/fat. |